8:50 am Chair’s Opening Remarks
Unleashing the Full Therapeutic Impact of Neoantigen-Targeted Cancer Vaccines With Optimised Design & Delivery to Invoke a Durable Immune Response
9:00 am Revolutionising Cancer Treatment: AI-Driven Personalised Vaccines
Synopsis
- Introducing AI-mediated personalised cancer vaccine platform
- Overviewing the proprietary neoantigen identification process that reduces development time to two weeks
- Implementing competitive differentiation through AI-driven vaccine design and rapid deployment
9:30 am Personalised Cancer Vaccine TG4050 in Resected Locally Advanced Head & Neck Squamous Cell Carcinoma (HNSCC) Patients
Synopsis
- Reviewing TG4050, an individualised immunotherapy being developed for solid tumours that is based on Transgene’s myvac® technology and powered by NEC’s longstanding artificial intelligence (AI) and machine learning expertise
- Discussing how TG4050 is being evaluated in a randomised multicenter Phase I/II clinical trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers
- Assesing 24-month follow up clinical and translational data from patients enrolled in the Phase I trial will be presented
10:00 am Morning Break & Networking
Reaching the Full Therapeutic Potential of Neoantigen-Targeted Cell Therapies & Beyond to Improve Patient Outcome
11:00 am A Personalised Neo-antigen Viro-Immunotherapy Platform for Human Solid Tumours
Synopsis
- How to identify immunogenic neoantigen epitopes? Is computational prediction sufficient?
- How to optimise tumour-targeted replicating oncolytic virus to unlock the power of virotherapy for cancer treatment?
- How to combine oncolytic viruses and neoantigens as a synergistic frontier for cancer treatment?
11:30 am A First-in-Human Phase I/IIa Trial of Personalised Tumour-Trained Lymphocytes (pTTL) Derived From Regional Lymph Nodes for the Treatment of Colorectal Cancer
Synopsis
- Examining pTTL (personalised Tumour-Trained Lymphocytes), a novel adoptive T-cell therapy product targeting tumour neoantigens. It is applicable to any cancer type for which neoantigens can be identified
- Understanding how therapy is personalised, tailored for the patient’s own tumour and consists of autologuous neoantigen selected T-cells derived from regional lymph nodes (RLN)
- Unveiling a first-in-human trial of pTTL in stage IV colorectal cancer is ongoing
12:00 pm Highly Optimised Autologous T Cell Therapy Following Cancer Vaccination
Synopsis
- Reviewing detailed characterisation of the immune response in cancer patients to neo Ag and TAA vaccination
- Pioneering the use of immune screening to successfully harvest vaccine-Ag-specific T cells as the basis for T cell therapy
- Creating highly optimised GMP in vitro expansion of vaccine-Ag specific T-cells for therapy
12:30 pm Targeting Cancer & Senescence Associated HERVs With mRNA & Adenovirus Encoded Antigens
Synopsis
- Discussing human endogenous retroviruses (HERVs) as emerged as possible immunotherapeutic targets for cancer and cell senescence associated diseases
- Reviewing how HERVOLUTION have developed mRNA and viral vector delivered HERV antigens forming HERV-like-particles within transduced cells
- Examining unique immunostimulatory mutations and viral chimerism allows effective break of immunological tolerance and anti-cancer and senolytic efficacy
1:00 pm Lunch & Networking
Optimising Manufacturing Efficiency of Neoantigen Therapies to Facilitate the Rapid Administration of High-Quality Therapies to Patients
2:00 pm Neomatrix: An Innovative, Fully-Synthetic DNA Platform for Next Generation Cancer Vaccines
Synopsis
- Evaluating how neoantigen identification is key for the design of personalised cancer vaccines and the requirements of prediction algorithm
- Enhancing a fast and reliable manufacturing technology and how synthetic DNA allowed the production of NCV in few days, without complex upstream and downstream procedures
- Investigating a efficient delivery method by using Electroporation which enhances gene expression and acts as adjuvant of immune response
2:30 pm Roundtable Discussion: Leveraging Technological Advances, Novel Manufacturing Approaches & External Partners to Safeguard Production Timeliness & Enhance the Quality of Autologous Neoantigen Therapies
Synopsis
- Considering manufacturing and quality control testing of personalised neoantigen platforms to guide platform choice for autologous therapies
- Turning to novel manufacturing technologies such as cell-free DNA production for rapid therapeutic manufacture whilst maintaining purity and regulatory adherence
- Evaluating quality, production efficiency and cost of external suppliers to make informed partnering decisions
3:15 pm Afternoon Break & Networking
Spotlighting Advances in Immune System Monitoring to Facilitate Accurate, Real-Time Understanding of Patient Response & Therapeutic Effect
4:00 pm Fireside Chat: Creating Alignment in Immune Monitoring & Interpretation of Read Outs to Increase Investment Opportunities & Accurately Measure Clinical Efficacy
Synopsis
- Creating a robust, methodical protocol for monitoring and analysing immune response to enable investors to contextualise and compare therapeutic efficacy
- Ensuring appropriate read outs and biomarkers are selected for immune monitoring to accurately evaluate immunogenicity of neoantigen vaccines and cell therapies
- Determining a desired level of de novo and secondary immune response to quantify efficacy
4:30 pm Reduction of Circulating Naïve Tregs & gMDSCs Mediated by NEO-201 & Low Levels of Soluble MICA are Prognostic Factors for Efficacy of Combined Treatment With NEO-201 & Pembrolizumab in Adults With Solid Tumours Resistant to Prior Checkpoint Inhibitors
Synopsis
- Examining the Accumulation of immunosuppressive cells in the TME, such as Tregs and gMDSCs is one of the mechanisms of tumour resistance to checkpoint inhibitors
- Understanding how NEO-201 mediates the killing of targets cells expressing core 1 O-glycans (including cancer cells and immunosuppressive cells) through ADCC and CDC. Elimination of circulating gMDSCs and Tregs mediated by NEO-201 may overcome resistance to checkpoints inhibitors
- Discussing levels of immunosuppressive cells and soluble factors that affect NK cells cytotoxic activity after treatment with NEO-201 can be used as prognostic factors for the efficacy of treatment with NEO-201 alone or in combination with other anti-cancer drugs